DTIL

Precision BioSciences, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-12

Figures on this page computed 2026-11-08 12:57 UTC

Last close

8.12USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-12

  • n/aP/E

    We do not hold this figure for this company, so there is nothing to place.

    Price / Earnings per Share (diluted)

    Source
    computed
    Fiscal year
    2025
    Accession
    0001628280-26-017019
    Reported in
    USD
    • computed
    • 10-K for 2025, filed 2026-03-12

    The filing itself

  • n/aROIC

    We do not hold this figure for this company, so there is nothing to place.

    NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash

    Source
    computed
    Fiscal year
    2025
    Accession
    0001628280-26-017019
    Reported in
    USD
    • 10-K for 2025, filed 2026-03-12
    • 10-K for 2025, filed 2026-03-12
    • 10-K for 2025, filed 2026-03-12
    • 10-Q for 2025, filed 2026-11-03
    • 10-K for 2025, filed 2026-03-12
    • 10-Q for 2025, filed 2026-11-03

    The filing itself

  • -133.4%Net margin

    Net Income / Revenue x 100

    Source
    computed
    Fiscal year
    2025
    Accession
    0001628280-26-017019
    Reported in
    USD
    • 10-K for 2025, filed 2026-03-12
    • 10-K for 2025, filed 2026-03-12

    The filing itself

  • -192.4%FCF margin

    Free Cash Flow / Revenue x 100

    Source
    computed
    Fiscal year
    2025
    Accession
    0001628280-26-017019
    Reported in
    USD
    • 10-K for 2025, filed 2026-03-12
    • 10-K for 2025, filed 2026-03-12

    The filing itself

  • n/aDebt/equity

    We do not hold this figure for this company, so there is nothing to place.

    Total Debt / Shareholders' Equity

    Source
    computed
    Fiscal year
    2025
    Accession
    0001628280-26-017019
    Reported in
    USD
    • 10-K for 2025, filed 2026-03-12
    • 10-Q for 2025, filed 2026-11-03

    The filing itself

  • n/aDividend yield

    We do not hold this figure for this company, so there is nothing to place.

    Source
    computed
    Taken on
    2026-11-07
    Reported in
    USD
    • computed

All from 100

lens 2 of 9

Sales

488
2016-12-31 to 2025-12-31100 at the start488
Sales: 100.00 on 2016-12-31 to 488.44 on 2025-12-31, up 388%.

Shares in issue

656
2021-12-31 to 2025-12-31100 at the start656
Shares in issue: 100.00 on 2021-12-31 to 655.64 on 2025-12-31, up 556%.
  • Profit, where the first year is 100: n/aNot enough filed years carry this line for it to be drawn. No line is drawn flat in its place.

Sales is at 488, Shares in issue is at 656, against 100 in 2016.

Sales is at 488, Shares in issue is at 656, against 100 in 2016.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-12

  • Sales, where the first year is 100488
    Source
    filed
    Statement
    income
    Fiscal year
    2025
    Accession
    0001628280-26-017019
    Reported in
    USD

    The filing itself

  • Profit, where the first year is 100n/a

    Not held.

    Source
    filed
    Statement
    income
    Fiscal year
    2025
    Accession
    0001628280-26-017019
    Reported in
    USD

    The filing itself

  • Shares in issue, where the first year is 100656
    Source
    filed
    Statement
    income
    Fiscal year
    2025
    Accession
    0001628280-26-017019
    Reported in
    USD

    The filing itself

Filed figures cite the filing they come from; figures marked Market data are quotes as of the date shown. Not a recommendation and not advice.

Past figures are not a forecast. Anything we modelled is labelled as ours. You can lose money on any security.